Company: ADPT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103752
Chunk: 40

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 40
---
itative Assessment(2)       |     |         | Achieved        |     |        |  15 | % |
|                                  |     | Complete Strategic Review (15%)    |     | Objective Strategic Milestone(3) |     |         | Achieved        |     |        |  15 | % |
| MRD (15%)                        |     | Diagnostic and Clinical Testing(4) |     | Quantitative Assessment          |     |         | Achieved        |     |        |  15 | % |
| Immune Medicine (25%)            |     | Discovery and Pipeline(5)          |     | Qualitative Assessment           |     |         | Achieved 3 of 4 |     |        |  20 | % |
| Employee Engagement Kicker (10%) |     | Employee Retention(6)              |     | Quantitative Assessment          |     |         | Achieved        |     |        |  10 | % |
| TOTAL                            |     |                                    |     |                                  |     |         |                 |     |        | 105 | % |

| (1) | The threshold MRD (clinical and MRD pharma) revenue goal was $130 million, the median goal was $140 million and the stretch goal was $150 million. We achieved $146 million. No interpolation between these goals was applied to the resulting payout. |

| (2) | Cash burn targets were consistent with our path to profitability for the MRD segment and overall capital allocation strategy, which the compensation and human capital committee viewed as realistically attainable and important for shareholders. |

| (3) | An outcome of our strategic review was to reorganize and restructure our business into two segments, MRD and Immune Medicine. |

30

| (4) | MRD goals were composed of growth in clonoSEQ clinical testing and achievement of certain booking metrics for MRD Pharma. |

| (5) | Immune Medicine goals were based on identifying candidates for future investments, discovering novel targets, and completing IND-ready end-to-end testing. |

| (6) | There was an additional 10% kicker for employee engagement that was achieved and paid out. Our engagement was assessed as a function of an employee retention target, which was based on trailing 12-month voluntary turnover for the calendar year. |

For 2024, performance against corporate goals was above target, with the company meeting or exceeding the target performance level for most goals. Accordingly, the corporate performance